Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LTSL-BPNF-doxorubicin
- Development stage
- Preclinical
- Lead developer
- University of Bradford
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**LTSL-BPNF-doxorubicin** is an experimental lysolipid temperature-sensitive liposomal nanoparticle formulation that co-encapsulates black phosphorus nanoflakes and doxorubicin for light-triggered prostate-cancer therapy. Near-infrared laser exposure activates the black phosphorus component to generate photothermal heating and reactive oxygen species, while the temperature-sensitive liposome promotes doxorubicin release. Doxorubicin contributes cytotoxic activity through DNA intercalation and topoisomerase II poisoning. The formulation showed antiproliferative activity in in-vitro PC-3 and DU 145 prostate-cancer models, with enhanced activity following near-infrared irradiation; it has not been reported as a clinical-stage or marketed product. ([mdpi.com](https://www.mdpi.com/1422-0067/25/1/115))
- Other names
- LTSL-BPNF-DoxLTSL-BPNF-doxorubicin
02
Targets
DNATOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)
Beyond the preview
Go deeper on LTSL-BPNF-doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LTSL-BPNF-doxorubicin.